Disease relevance of MEDIGOXIN

• Eighteen patients with atrial fibrillation were given digoxin 0.13 mg twice daily for 3 weeks and beta-methyldigoxin 0.10 mg twice daily for another 3 weeks [1].
• The average maintenance does of beta-methyldigoxin in 102 cases of congestive heart failure with atrial fibrillation was 0.177 mg per day [2].
• Digitalis (beta-methyldigoxin 1.27 X 10(-6) M) caused VTAs and ventricular fibrillation (VF) in all the hearts [3].
• In patients with cirrhosis the proportion of serum beta-methyldigoxin averaged 77.7% of the total digoxin concentration, whereas the proportion was only 37.5% in healthy volunteers [4].
• Beta-methyldigoxin does not appear to be a satisfactory alternative to other effective agents available for the prompt correction of paroxysmal reciprocating atrioventricular tachycardia [5].

High impact information on MEDIGOXIN

• A biphasic response to methyldigoxin was observed, with initial action potential prolongation, maximal at 20 min post-infusion, followed by significant action potential shortening which persisted to the end of the study period at 40 min [6].
• Digoxin and beta-methyldigoxin were evaluated pharmacokinetically in terms of P-glycoprotein (P-gp)-mediated drug interactions in rats [7].
• Measurement of beta-methyldigoxin level in serum from patients by enzyme immunoassay using novel specific antiserum with a phenyl boric acid column [8].
• Pharmacokinetics of beta-methyldigoxin in subjects with normal and impaired renal function [9].
• Suspension-cultured DIGITALIS LANATA cells, known to form beta-methyldigoxin from beta-methyldigitoxin without any by-products, were not able to 12beta-hydroxylate digitoxin efficiently when cultivated in the cell culture medium devised by Murashige and Skoog [10].

Chemical compound and disease context of MEDIGOXIN

• Effect of metildigoxin (beta-methyldigoxin) on congestive heart failure as evaluated by multiclinical double blind study [11].

Biological context of MEDIGOXIN

• Significant decreases in left ventricular ejection time and heart rate were observed after the oral and intravenous administration of beta-methyldigoxin [12].
• Pharmacokinetics of beta-methyldigoxin in healthy humans II: Oral studies and bioavailability [13].
• Preparation of beta-methyldigoxin by hydroxylation of beta-methyldigitoxin in fermenter cultures of Digitalis ianata [14].
• 4 A small progressive and significant increase in cardiac output was observed, though left ventricular filling pressures were not significantly reduced after methyldigoxin [15].
• Tissue distribution and elimination of digoxin and methyldigoxin after single and multiple doses in dogs [16].

Anatomical context of MEDIGOXIN

• A sum of four exponentials described the plasma beta-methyldigoxin data with apparent half-lives of 0.04, 0.33, 3.5, and 41 hr. beta-Methyldigoxin was 10% plasma protein bound and had a red blood cell-plasma water partition coefficient of 0 [17].
• The present experiments demonstrate that after pretreatment of isolated porcine coronary arteries with therapeutic (2.5 X 10(-9) M) was well as with toxic (10(-6) M) doses of beta-methyldigoxin the serotonin-induced contractions were significantly amplified [18].
• The effect of drugs from the class of cardiac (methyldigoxin, verapamil, propranolol), antiepileptic (carbamazepine), sedative (diazepam) and antihistaminic (promethazine) drugs on Na,K-ATPase activity of plasma membranes was studied in rat brain synaptosomes [19].
• This can be ascribed to a higher absorption rate of beta-methyldigoxin from the digestive tract [2].
• Interaction between verapamil and beta-methyldigoxin. Study by 86Rubidium uptake in erythrocytes [20].

Associations of MEDIGOXIN with other chemical compounds

• There were no significant differences between digoxin and beta-methyldigoxin in their effects on the ECG (R-R intervals, T-wave, Q-T duration) [1].

Gene context of MEDIGOXIN

• Both patients responded to medications of diuretics, methyldigoxin and angiotensin converting enzyme inhibitor [21].
• Digoxin concentrations as well as 3435C > T and 2677G > A,T ABCB1 single nucleotide polymorphisms, were determined in 77 patients administered digoxin (0.25 mg daily) and methyldigoxin (0.50 mg daily), some of them co-medicated with known P-glycoprotein (Pgp) inhibitors [22].

Analytical, diagnostic and therapeutic context of MEDIGOXIN

• Influence of hemoperfusion on the concentration of beta-methyldigoxin and hormones in plasma [23].
• The authors compared serum beta-methyldigoxin (MDx) levels in digitalized patients by enzyme immunoassay (EIA) using anti-MDx 3'-hemisuccinate BSA antiserum (antiserum-I) with commercial antidigoxin antiserum (antiserum-II) [8].
• Comparable plasma concentration values (1.0 ng/ml for digoxin, 1.1 ng/ml for beta-methyldigoxin, mean values) were obtained by radioimmunoassay, but the 86Rb-technique gave significantly higher values (mean 1.5 ng/ml) for beta-methyldigoxin [1].
• 1 Medigoxin (Lanitop) 300 microgram/day and digoxin (Lanoxin) 500 microgram/day were compared in cross-over studies on healthy volunteers and on patients with uncontrolled atrial fibrillation [24].
• Determination of beta-methyldigoxin and its metabolites by high-performance liquid chromatography and fluorescence polarization immunoassay [25].

References